MEDIA | Ausbiz
Avecho CEO Dr Paul Gavin was interviewed by Ausbiz last week to discuss the company’s strategic partnership with Sandoz and detailed insights into the development of our proprietary CBD softgel capsule for insomnia treatment.
During the interview, Dr Gavin elaborated on the financial significance of the partnership and how it will help to strengthen the clinical development timeline:
“This capital injection from Sandoz enables us to progress to the interim analysis phase without financial constraints. Our Phase III trial is designed to include 500 patients, with an interim analysis planned at the 200-patient mark. We anticipate completing patient recruitment this year, positioning us for preliminary results in early 2026.”
Upon successful completion of the Phase III trial and regulatory approval, Avecho’s pharmaceutical CBD product has the potential to become the first registered pharmaceutical CBD formulation globally for insomnia.